MedTrace Logo

Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2

NCT02526485 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-02-17

No results posted yet for this study

Summary

The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.

Conditions

  • Heparin-induced Thrombocytopenia

Interventions

PROCEDURE

Blood Draw

A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Phillips Phillips, MD · Vanderbilt University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-09-05
Completion
2018-09-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526485 on ClinicalTrials.gov